What happened with MMEDV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MiniMed Group serves people with type 1 diabetes and those with type 2 diabetes who need intensive insulin therapy. Its MiniMed 780G system combines an insulin pump, a continuous glucose sensor and SmartGuard software, which uses sensor readings to adjust insulin delivery automatically. For people who inject insulin rather than use a pump, MiniMed Go combines the InPen smart insulin pen with glucose monitoring and an app.
Customers buy pumps or pens, then regularly replace sensors and insulin-delivery supplies to keep using the systems. Those repeat purchases generate most of MiniMed’s revenue, with glucose monitoring its largest sales category. It sells to patients, distributors, healthcare providers and institutions. Most customers rely on private insurance or government healthcare coverage to support purchases. Most revenue comes from outside the United States; U.S. distribution mainly uses the durable medical equipment channel rather than pharmacies.
The business depends on retaining users and maintaining reimbursement and supply. Abbott exclusively supplies third-party glucose sensors for certain systems, and the agreement restricts MiniMed from buying or distributing sensors from certain Abbott competitors. Convatec is its sole infusion-set supplier. Products and changes need regulatory authorization, and MiniMed may promote devices only within their approved labeling.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
With roughly 70% of revenue outside the United States, MiniMed depends on winning and keeping pump users against international rivals including mylife Diabetes Care and Medtrum.
Tandem Diabetes Care and MiniMed compete for much the same patients needing intensive insulin therapy in U.S. and international markets, selling long-lived automated insulin pumps and supplies patients replace regularly. Watch Tandem’s t:slim X2 and Mobi pump sales: winning users also brings repeat cartridge and infusion-set business.
Insulet’s Omnipod competes with MiniMed’s automated insulin-delivery systems for insulin-dependent patients, and MiniMed’s planned Fit patch pump targets Omnipod’s tubeless, body-worn format. Watch Omnipod adoption as MiniMed prepares to enter that format, where patients repeatedly replace disposable insulin-delivery Pods.
Dexcom and MiniMed compete to sell sensors that continuously track glucose to people managing diabetes, so sensor uptake and pricing matter to both. Watch Dexcom’s sensor sales and pricing against MiniMed’s CGM revenue, its largest product category in the fiscal year ended April 24, 2026.
Abbott both competes with MiniMed through Libre glucose sensors and supplies the third-party sensors used in certain MiniMed automated-delivery and smart-pen systems, with MiniMed paying Abbott per sensor. Watch that supply partnership, which also extends to sensors measuring both glucose and ketones for exclusive integration with MiniMed smart dosing systems.
Beta Bionics’ iLet competes with MiniMed’s automated insulin-delivery systems for U.S. type 1 diabetes patients, with orders typically paid by third-party payors directly or through distributors. Watch iLet user growth: its users must buy compatible cartridges and infusion sets rather than third-party alternatives, tying pump adoption to recurring supply sales.
Medtronic retained approximately 90% of MiniMed after its IPO and provides transition services, so the tie is ownership and separation costs, not independent competition in diabetes devices. Watch the cost of replacing those services: MiniMed’s historical allocated corporate costs may understate what it needs to spend to operate independently.
Abbott Laboratories earningsABT
Abbott competes for CGM users with Libre and supplies sensors for some MiniMed systems, so its report shows how the sensor business of both a rival and a supplier is developing.
Watch Abbott's disclosures about its glucose-sensor business and whether it discusses its supply relationship with MiniMed. Stronger sensor activity would show Abbott gaining weight both as a competitor for CGM users and as an outside supplier to some MiniMed systems. Weaker activity would soften the competitive signal, but would not by itself show a supply problem.
DexCom, Inc. earningsDXCM
Dexcom and MiniMed Group both sell continuous glucose sensors to people with diabetes, so Dexcom's sales and pricing show the competitive conditions facing MiniMed's largest product category.
Read Dexcom's sensor sales alongside its pricing. Growing sales with prices holding would point to firm CGM demand and a capable rival in MiniMed's largest product category. If sales rely on lower prices, that would point to price pressure that can erode sensor economics.
Tandem Diabetes Care, Inc. earningsTNDM
Tandem Diabetes Care competes with MiniMed Group for people needing intensive insulin therapy, and its pump and supply sales show whether that rival is attracting users and repeat purchases.
Read Tandem's pump sales alongside sales of recurring supplies such as cartridges and infusion sets. Growth in both would show that it is attracting users and generating follow-on purchases, strengthening competition for MiniMed's pumps and consumables. Weak pump sales, or supplies that do not follow, would show less momentum in one part of that business.
MiniMed Group, Inc. earningsThis company
CGMs are MiniMed Group's largest product category, and this report will show whether growth in CGMs and consumables is turning into stronger gross profit and operating cash flow.
Read CGM and consumables sales alongside gross profit and cash from operations. If sales keep growing while profit and cash improve, MiniMed is converting revenue growth into stronger earnings and internally generated cash. If sales rise but profit or cash weakens, lower-margin CGMs and the costs of operating independently are still absorbing the gains.
